Haploidentical HCT for Severe Aplastic Anemia

Given intravenously (IV)

Given intravenously (IV)

Given intravenously (IV)

Given intravenously (IV)

Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated

TLI will be given at 800 cGy total dose in 4 fractions.

The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.

Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)

CD45RA-depleted DLI will be given at least ONE week after engraftment